Fate Therapeutics begins Phase II trial of FT819 for lupus nephritis

Phase 2FT819Positive

AI Analysis

Summary

Fate Therapeutics has initiated RECLAIM-LN, a Phase II trial evaluating FT819 in patients with moderate-to-severe systemic lupus erythematosus with Class III or IV lupus nephritis, with the first patient treated.

Clinical Trial Data

Phase

Phase II

Importance:5/10

Sentiment:

0.30

Phase II trial initiationlupus nephritiscell therapyRECLAIM-LN

Related Companies

$FATE

Read the original article

Published by Clinical Trials Arena on August 17, 2026 9:55 AM

Read Original